Tokyo, March 12 -- National University Corporation - Hokkaido has issued a Notice of Procurement (Goods & Services) on Mar 11, 2026. Here are other related details:
Classification:
0004 Medical & Pharmaceutical Products
Summary:
⑴ Official in charge of disbursement of the procuring entity : Yuji Nishikawa, President, Asahikawa Medical University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Blinatumomab (Genetical Recombination) (38.5 μg/1 vial) 153 vials
B Enfortumab Vedotin (Genetical Recombination) (33.7 mg/1 vial) 448 vials
C Durvalumab (Genetical Recombination) (500 mg/10 mL/1 vial) 584 vials
D Fulvestrant (250 mg/5 mL/2 syringes/1 case) 838 cases
E Epcoritamab (Genetical Recombination) (48 mg/0.8 mL/1 vial) 48 vials
F Risankizumab (Genetical Recombination) (360 mg/2.4 mL/1 kit) 140 kits
G Risankizumab (Genetical Recombination) (75 mg/0.83 mL/1 syringe) 300 syringes
H Tarlatamab (Genetical Recombination) (10 mg/1 vial) 30 vials
I Efgartigimod Alfa (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (1008 mg/5.6 mL/1 vial・11200 units/5.6 mL/1 vial) 93 vials
J Efgartigimod Alfa (Genetical Recombination) (400 mg/20 mL/1 vial) 68 vials
K Ravulizumab (Genetical Recombination) (300 mg/3 mL/1 vial) 192 vials
L Sacituzumab Govitecan (Genetical Recombination) (200 mg/1 vial) 194 vials
M Axicabtagene ciloleucel (1 bag/1 case) 1 case
N Mepolizumab (Genetical Recombination) (100 mg/1 mL/1 kit) 218 kits
O Avalglucosidase Alfa (Genetical Recombination) (103 mg/1 vial) 234 vials
P Tildrakizumab (Genetical Recombination) (100 mg/1 vial) 51 syringes
Q Canakinumab (Genetical Recombination) (150 mg/1 vial) 190 vials
R Onasemnogene abeparvovec (1 set) 1 set
S Nusinersen Sodium (12.63 mg/5 mL/1 vial) 3 vials
T Elranatamab (Genetical Recombination) (76 mg/1.9 mL/1 vial) 110 vials
U lisocabtagene maraleuce (1 set/1 case) 1 case
Ⅴ Pomalidomide (4 mg/7 capsules/1 case) 90 cases
W Avelumab (Genetical Recombination) (200 mg/1 vial) 286 vials
X Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (1800 mg/15 mL/1 vial・30000 units/15 mL/1 vial) 374 vials
Y Guselkumab (Genetical Recombination) (100 mg/1 mL/1 syringe) 151 syringes
Z Pegfilgrastim (Genetical Recombination) (3.6mg/0.36mL/1kit) 328kits
AA Pegfilgrastim (Genetical Recombination) (3.6 mg/0.36 mL/1 syringe) 359 syringes
AB Aflibercept (Genetical Recombina-
tion) (21.03 mg/0.184 mL/1 kit) 342 kits
AC Nivolumab (Genetical Recombina-
tion) (240 mg/24 mL/1 vial) 1115 vials
AD Carfilzomib (40 mg/1 syringe) 273 syringes
AE Dinutuximab (Genetical Recombination) (17.5 mg/5 mL/1 vial) 24vials
AF Paclitaxel (100 mg/1 vial) 1424 vials
AG Trastuzumab Deruxtecan (Genetical Recombination) (107 mg/1 vial) 624 vials
AH Datopotamab Deruxtecan (Genetical Recombination) (108 mg/1 vial) 267 vials
AI Pertuzumab (Genetical Recombina-
tion)・Trastuzumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (600 mg/10 mL/1 vial) (600 mg/10 mL/1 vial) (20000 units/10 mL/1 vial) 553 vials
AJ Polatuzumab Vedotin (Genetical Recombination) (38 mg/1 vial) 462 vials
AK Atezolizumab (Genetical Recombination) (1200 mg/20 mL/1 vial) 186 vials
AL Satralizumab (Genetical Recombination) (120 mg/1 mL/1 syringe) 51 syringes
AM Trastuzumab Emtansine (Genetical Recombination) (106 mg/1 vial) 177 vials
AN Faricimab (Genetical Recombination) (21 mg/0.175 mL/1 syringe) 176 syringes
AO Ustekinumab (Genetical Recombination) (45 mg/0.5 mL/1 syringe) 646 syringes
AP Inebilizumab (Genetical Recombination) (100 mg/10 mL/3 vials/ 1case) 4 cases
AQ Infliximab (Genetical Recombination) (100 mg/1 vial) 600 vials
AR Ramucirumab (Genetical Recombination) (500 mg/50 mL/1 vial) 126 vials
AS Ixekizumab (Genetical Recombination) (80 mg/1 syringe/1 kit) 302 kits
AT Brentuximab Vedotin (Genetical Recombination) (55 mg/1 vial) 66 vials
AU Leuprorelin Acetate (22.5 mg/1 syringe) 372 syringes
AV Pembrolizumab (Genetical Recombination) (100 mg/4 mL/1 vial) 2464 vials
AW Sugammadex Sodium (200mg/2mL/
10 syringe/1 case) 452 cases
AX SAPIEN 3 Ultra RESILIA System (S3URCM23J 23mm for Aortic valve) or its equivalent 23 sets
AY SAPIEN 3 Ultra RESILIA System (S3URCM26J 26 mm for Aortic valve) or its equivalent 10 sets
AZ SOUNDSTAR eco Catheter (10439236
8Fr 90cm for GE Healthcare) or its equivalent 90 pieces
BA OCTARAY (D160903 7.5 Fr effective length 113 cm 48+4 poles spacing 3-3-3-3-3mm) or its equivalent 97 pieces
BB IMPELLA CP SmartAssist Set (0048-0024-JP) or its equivalent 14 sets
BC Cobalt XT DR MRI IS-1/DF-4 (DDPA
2D4 IS-1/DF4) or its equivalent 9 pieces
⑷ Delivery period : From 1, June, 2026 through 31, May, 2027
⑸ Delivery place : Asahikawa Medical University Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 4 and 5 of the Regulation concerning the Contract for Asahikawa Medical University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A, Grade B or Grade C qualification during fiscal 2026 in the Hokkaido area in Sales of products for participating in tenders by Single qualification for every ministry and agency,
C have the following Grade qualification, for each item in 5 ⑶above,
A~AW prove to have obtained the first-class license for selling drugs in accordance with The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
AX~BC prove to have registered with the relevant authorities, in accordance with The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, to initiate business of selling medical appliances,
D not be currently under a suspension of business order as instructed by the President, The National University Corporation Asahikawa Medical University.
⑺ Time limit of tender : 17 : 00 1, May, 2026
⑻ Contact point for the notice :
A~AW Ryuji Sato, Procurement Section, Accounting Division, Asahikawa Medical University, 2-1-1-1 Midorigaokahigashi Asahikawa-shi Hokkaido 078-8510 Japan, TEL 0166-69-3071
AX~BC Takashi Sunada, Procurement Section, Accounting Division, Asahikawa Medical University, 2-1-1-1 Midorigaokahigashi Asahikawa-shi Hokkaido 078-8510 Japan, TEL 0166-69-3067
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.
Disclaimer: Curated by HT Syndication.
